Jay Hsu Selected Research

Lurasidone Hydrochloride

3/2022	Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.
1/2022	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis.
10/2021	Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.
6/2021	Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
1/2017	Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
10/2016	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study.
1/2016	Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
1/2016	Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
11/2015	The development of lurasidone for bipolar depression.
8/2014	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jay Hsu Research Topics

Disease

14	Schizophrenia (Dementia Praecox) 03/2022 - 02/2013
3	Body Weight (Weight, Body) 01/2022 - 02/2013
3	Psychomotor Agitation (Akathisia) 10/2021 - 05/2013
3	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 01/2019
3	Psychotic Disorders (Schizoaffective Disorder) 01/2019 - 02/2013
2	Weight Gain 10/2021 - 05/2013
2	Sleepiness 10/2021 - 02/2014
2	Nausea 10/2021 - 02/2014
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020 - 01/2019
2	Headache (Headaches) 01/2020 - 02/2014
2	Bipolar Disorder (Manic Depressive Psychosis) 01/2016 - 11/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2021
1	Edema (Dropsy) 07/2006
1	Pancreatitis 07/2006
1	Neurogenic Inflammation 07/2006

Drug/Important Bio-Agent (IBA)

16	Lurasidone Hydrochloride FDA Link 03/2022 - 02/2013
9	Antipsychotic Agents (Antipsychotics)IBA 03/2022 - 02/2013
3	LipidsIBA 01/2022 - 02/2013
3	ProlactinIBA 01/2022 - 02/2013
3	4- (3,4- dichlorophenyl)- 1,2,3,4- tetrahydronaphthalen- 1- amineIBA 01/2021 - 01/2019
2	LithiumIBA 01/2016 - 11/2015
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2016 - 11/2015
2	Insulin (Novolin)FDA Link 08/2014 - 02/2013
2	Glucose (Dextrose)FDA LinkGeneric 08/2014 - 02/2013
1	Risperidone (Risperdal Consta)FDA LinkGeneric 06/2021
1	Therapeutic UsesIBA 01/2016
1	Pharmaceutical PreparationsIBA 11/2015
1	Quetiapine Fumarate (Seroquel)FDA Link 11/2013
1	Olanzapine (Zyprexa)FDA Link 05/2013
1	TRPV Cation ChannelsIBA 07/2006
1	SecretagoguesIBA 07/2006
1	Amylases FDA Link 07/2006
1	CeruletideIBA 07/2006
1	Peroxidase (Myeloperoxidase)IBA 07/2006
1	Peptides (Polypeptides)IBA 07/2006
1	Substance PIBA 07/2006

Therapy/Procedure

2	Therapeutics 01/2016 - 11/2015
1	Patient Readmission 01/2016
1	Intraperitoneal Injections 07/2006
1	Ganglionectomy 07/2006